moyamoya disease
Conditions
Interventions
Experimental group:Preoperative ultrasound-guided ipsilateral stellate ganglion block
Control group:No intervention
Sponsors
Drum Tower Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18-65 years; 2. Confirmed cerebrovascular lesions of moyamoya disease by digital subtraction angiography (DSA) or magnetic resonance angiography (MRA); 3. Intended to undergo elective revascularization surgery; 4. American Society of Anesthesiologists (ASA) classification I-III; 5. No severe cardiopulmonary dysfunction; 6. Written informed consent signed by the patient or legal representative, voluntarily participating in the study and cooperating with follow-up; 7. No severe neurological deficits preoperatively.
Exclusion criteria
Exclusion criteria: 1. Absolute contraindications for SGB implementation: patient refusal or inability to cooperate, presence of infected tumors or anatomical abnormalities at the puncture site, confirmed hypersensitivity to local anesthetics (e.g., ropivacaine, lidocaine), severe coagulation disorders, contralateral phrenic nerve palsy or vocal cord palsy, glaucoma (particularly angle-closure glaucoma); 2. Concurrent severe systemic diseases, including severe hepatic or renal insufficiency (Child-Pugh C grade or eGFR 180 mmHg or diastolic>110 mmHg) or diabetes mellitus (HbA1c>9%), active infections (e.g., pneumonia, sepsis) or immune disorders (e.g., systemic lupus erythematosus); 4. Preoperative moderate to severe cognitive impairment (MoCA score 1/3 of the middle cerebral artery supply region); 5. Pregnancy or lactation; 6. Participation in other clinical trials within 3 months prior to surgery; 7. Other reasons deemed unsuitable for study participation by investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence and frequency of transient neurological events (TNEs); | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative recovery quality score;Incidence of postoperative cerebral infarction;Cognitive assessment;IL-6;TNF-a;IL-8;IL-10;Intraoperative TCD monitoring;Intraoperative hemodynamic monitoring;Intraoperative use of vasoactive drugs;Postoperative tube removal time;Postoperative pain scores;Postoperative analgesic medication use;Cerebral blood flow perfusion;length of stay;adverse safety events; | — |
Countries
China
Contacts
Public ContactRuan jiaping
Nanjing Drum Tower Hospital
Outcome results
None listed